Biotech Startups: Move Slow and Fix Things — Stanford Biotechnology Group
Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the t
Biotech Startups: Move Slow and Fix Things Mar 10 Written By Joel Bateman Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the tech industry and perceived falling costs associated with biotech startups have led to riskier and earlier funding for biotech startups. He outlines implications for the years ahead and offers ideas for biotech entrepreneurs to navigate the bump
saved by
related reading
- Tech vs Biotech - Celine Haliouacelinehh.com
- The future of biotech is founder-led | Tony Kulesa | Pillar VCpillar.vc
- The Biotech Delusion: Things No One Wants to Admitmattshlosberg.substack.com
- Fundraising for Founder-led Biotech – Matt Krisiloffmattkrisiloff.com
- “Build What’s Fundable” - by Kyle Harrison - Investing 101investing101.substack.com
- Heat Death: Venture Capital in the 1980s | Reaction Wheelreactionwheel.net
- Early-Stage Biotech Value Creation: The Roles of Equity and Partnershipsleadershipandbiotechnology.blogspot.com
- The Crisis of Venture Capital: Fixing America’s Broken Start-Up System - American Affairs Journalamericanaffairsjournal.org
- Anatomy of a Biotech Business Development Deal | Andreessen Horowitza16z.com
- Hub-and-Spoke Biotechs: BridgeBio - by Elliot Hershbergcenturyofbio.com
- Biotech’s Dulcius Ex Asperis: The Way Through This Downturn - RApportrapport.bio
- Go Big or Go Broke – The Middle Ground is Gonelinkedin.com